Original price was: $55.00.$46.75Current price is: $46.75.
Synthetic heptapeptide melanocortin receptor agonist supplied for MC4R signaling and neuroendocrine research models.
CAS Number: 189691-06-3
Form: Lyophilized Powder
Quantity: 10mg per vial
Purity: ≥99% (HPLC verified)
Molecular Formula: C₅₀H₆₈N₁₄O₁₀
Molecular Weight: 1,025.2 g/mol
Storage: −20°C recommended
Stability: 24+ months lyophilized
Category: Research Compounds
Use: Not for human or animal use. Research laboratory use only.
In stock
All major credit cards accepted
PT-141, also designated bremelanotide, is a synthetic cyclic heptapeptide that acts as an agonist at the neural melanocortin receptors, principally melanocortin-3 (MC3-R) and melanocortin-4 (MC4-R). Derived from the α-melanocyte-stimulating hormone (α-MSH) core sequence, it is used as a reference melanocortin receptor agonist in laboratory pharmacology. Precision Research Peptides supplies PT-141 as a research-grade compound for in vitro and preclinical investigation of melanocortin receptor binding, receptor signaling, and structure–activity relationships. This material is characterized for laboratory study of melanocortin signaling systems and is not offered for any diagnostic or clinical purpose. Not for human or animal use. Research laboratory use only.
All compounds referenced are supplied for laboratory and research applications only and are not for human consumption. PT-141 (bremelanotide) is investigated in receptor pharmacology as an agonist at the neural melanocortin receptors, a G protein–coupled receptor family in which MC3-R and MC4-R are the principal central subtypes.1 2 The melanocortin-4 receptor has been extensively characterized with respect to its expression, constitutive activity, and coupling to the Gs–adenylyl cyclase–cAMP pathway, and it serves as a common reference target in structure–activity studies of melanocortin ligands.1 As a cyclic analog of the α-MSH pharmacophore (His-Phe-Arg-Trp), PT-141 has been investigated for its role in melanocortin receptor binding and activation, and it is used alongside endogenous and synthetic melanocortin peptides to map agonist selectivity across receptor subtypes.2 4 Comparative work discriminating MC3-R versus MC4-R agonism illustrates how subtype-selective probes are developed and how partial versus full agonist behavior is quantified in cell-based signaling assays.4 In dedicated pharmacology characterization, the melanocortin receptor agonist bremelanotide has been examined using objective physiological monitoring methods, reflecting its use as a defined receptor-active reference agent in controlled study settings.3 Research involving PT-141 has examined its role in melanocortin signaling and receptor-level pharmacology rather than any downstream physiological outcome. Investigators typically employ recombinant receptor systems, radioligand or functional cAMP assays, and comparative agonist panels to characterize potency and selectivity across the melanocortin receptor subtypes. Not for human or animal use. Research laboratory use only.
A professional platform for accessing research compounds with clarity, consistency, and research-first standards.
From sourcing to fulfillment, every step of our process is structured around clarity, consistency, and professional research standards.
Our platform is built to support efficient research workflows with organized categories, standardized product presentation, and simple reordering.
Every product is presented in formats designed for stability, professional handling, and alignment with laboratory environments.
4.8 Stars
Our approach prioritizes clarity, structure, and transparency. Each compound is presented with research-focused documentation, neutral communication, and consistent labeling to support scientific workflows.
We believe long-term trust is built through precision, not promotion.
